ZYOMYX is a technology company.
ZYOMYX has raised $12.0M across 1 funding round.
ZYOMYX has raised $12.0M in total across 1 funding round.
Zyomyx is a privately held biotechnology company headquartered in Fremont, California, specializing in the development and commercialization of diagnostic platforms.[1][4][5] It primarily builds point-of-care tests for HIV/AIDS, such as a rapid CD4 cell count test that delivers results in under 10 minutes from a drop of blood without electricity, enabling minimally trained health workers to assess patient needs on-site at a potential cost of $6 per test.[6] The company serves global health initiatives targeting HIV management in resource-limited settings, solving the problem of inaccessible, infrastructure-dependent diagnostics by providing affordable, portable alternatives to tests costing $8–$15.[6] Zyomyx operates in biotechnology and medical equipment manufacturing, with reported revenue of $16.6 million and a small team of about 3 employees, though its growth has been hampered by financial challenges.[5]
Zyomyx emerged as an innovator in diagnostics, with its core technology focusing on point-of-care HIV testing validated through early proof-of-concept demonstrations.[6] Key early backing came from the Bill & Melinda Gates Foundation's HIV diagnostics initiative, which made Zyomyx its first investment; the foundation managed the deal amid the company's financial struggles, highlighting the product's potential despite risks.[6] Pivotal moments included partnerships explored with global players like Mylan N.V. starting in 2009, intensifying in 2012 at a J.P. Morgan conference as Zyomyx's cash dwindled, positioning Mylan as a potential distribution partner to scale the CD4 test globally.[6] Specific founding year and founder details are not detailed in available sources, but the company has evolved from HIV-focused diagnostics toward broader molecular assays for cell therapy, quality control, drug repositioning, and predictive toxicology.[4][7]
Zyomyx rides the trend of point-of-care diagnostics in global health, particularly for infectious diseases like HIV in developing regions where lab infrastructure is scarce.[6] Timing aligns with rising demand for rapid, affordable testing amid antiretroviral scale-up, amplified by philanthropic investments like the Gates Foundation's push for accessible tools.[6] Market forces favoring it include generic drug giants like Mylan's interest in ecosystem plays—pairing diagnostics with treatments to boost adherence without profit pressure on tests—and projections for millions of annual HIV tests.[6] It influences the ecosystem by pioneering low-cost biotech innovations, potentially enabling broader access to therapies and inspiring similar portable diagnostics in biotech.
Zyomyx's path forward hinges on securing stable funding or partnerships to overcome past financial hurdles, potentially reviving its CD4 test via Mylan-like deals or expanding into high-growth areas like cell therapy diagnostics.[6][7] Trends in personalized medicine, AI-driven toxicology, and global health equity will shape it, with demand for rapid assays in drug development and emerging pandemics offering tailwinds.[7] Its influence could evolve from niche HIV innovator to broader biotech enabler if it scales manufacturing, tying back to its core strength in making diagnostics accessible where they're needed most.[1][6]
ZYOMYX has raised $12.0M in total across 1 funding round.
ZYOMYX's investors include Genoa Ventures.
ZYOMYX has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series B in June 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2013 | $12.0M Series B | Genoa Ventures |